Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvalizumab and Neoadjuvant Chemotherapy in Ib-IIIb NSCLC
NCT04897386Phase 2Unknown
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC). Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04897386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04897386.